Who Exports Telmisartan from India — 413 Suppliers Behind a $11.0B Market
India's telmisartan export market is supplied by 413 active exporters who collectively shipped $11.0B across 11,086 shipments. CIPLA LIMITED leads with a 98.4% market share, followed by MYLAN LABORATORIES LIMITED and INTAS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 99.3% of total export value, reflecting a concentrated market structure.
Top Telmisartan Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading telmisartan exporter from India, holding a 98.4% share of the $11.0B market across 11,086 shipments from 413 exporters. The top 5 suppliers — CIPLA LIMITED, MYLAN LABORATORIES LIMITED, INTAS PHARMACEUTICALS LIMITED, ARISTO PHARMACEUTICALS PRIVATE LIMITED, ALEMBIC PHARMACEUTICALS LIMITED — collectively control 99.3% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (98.4%), MYLAN LABORATORIES LIMITED (0.6%), INTAS PHARMACEUTICALS LIMITED (0.1%), ARISTO PHARMACEUTICALS PRIVATE LIMITED (0.1%), ALEMBIC PHARMACEUTICALS LIMITED (0.1%).
Top Telmisartan Exporters from India
Ranked by export value · 413 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED CRESAR 40 TABLETSTELMISARTAN TABLETS 40 MG -TELMISARTAN TABLETS 20 MG - | $10.8B | 5 | 98.4% |
| 2 | MYLAN LABORATORIES LIMITED TELMISARTAN TABLETS 80MGTELMISARTAN TABLETS USP 80 MG 90BT TAB 15168 PACKSTELMISARTAN TABLETS USP 40 MG US 90BT 15225 PACKS | $61.5M | 4 | 0.6% |
| 3 | INTAS PHARMACEUTICALS LIMITED TELMISAR PLUS TABLET (TELMISARTAN 40MG &ARISTO TELVAS 80ARISTO TELVAS H 80/12.5 | $15.5M | 19 | 0.1% |
| 4 | ARISTO PHARMACEUTICALS PRIVATE LIMITED ARISTO TELVAS 80ARISTO TELVAS H 80/12.5ARISTO TELVAS H 40/12.5 | $11.6M | 10 | 0.1% |
| 5 | ALEMBIC PHARMACEUTICALS LIMITED TELMISARTAN TABLETS USP 80 MG 90BT TAB 15168 PACKSTELMISAR PLUS TABLET (TELMISARTAN 40MG &TELMISARTAN TABLETS USP 40 MG US 90BT 15225 PACKS | $11.0M | 12 | 0.1% |
| 6 | GLENMARK PHARMACEUTICALS LIMITED TELMISARTAN TABLETS 80MGTELMISARTAN TABLETS USP 80 MG 90BT TAB 15168 PACKSTELMISARTAN TABLETS USP 40 MG US 90BT 15225 PACKS | $9.3M | 17 | 0.1% |
| 7 | MICRO LABS LIMITED TELMISARTAN TABLETS USP 80 MG 90BT TAB 15168 PACKSARISTO TELVAS 80TELMISARTAN TABLETS USP 40 MG US 90BT 15225 PACKS | $8.9M | 23 | 0.1% |
| 8 | MSN LABORATORIES PRIVATE LIMITED ARISTO TELVAS 80ARISTO TELVAS H 80/12.5ARISTO TELVAS H 40/12.5 | $7.1M | 23 | 0.1% |
| 9 | INVENTIA HEALTHCARE LIMITED TELMISARTAN TABLETS USP 80 MG 90BT TAB 15168 PACKSTELMISAR PLUS TABLET (TELMISARTAN 40MG &TELMISARTAN TABLETS USP 40 MG US 90BT 15225 PACKS | $5.3M | 8 | 0.0% |
| 10 | MEDIWIN PHARMACEUTICALS TELMISAR PLUS TABLET (TELMISARTAN 40MG &OTHER-TELDAY 80 TABLETS NOS SIZE 10 X 10 TABLETSPHARMA DRUGS AND MEDI TELMISARTAN 80MG 3X10T PP AS PER INV | $5.1M | 3 | 0.0% |
| 11 | TORRENT PHARMACEUTICALS LTD TELMISAR PLUS TABLET (TELMISARTAN 40MG &CRESAR 40 TABLETSTELMISARTAN TABLETS 40 MG - | $3.7M | 7 | 0.0% |
| 12 | TEVAPHARM INDIA PRIVATE LIMITED TELMISARTAN TABLETS 80MG221791,TELMISARTAN 80MG T FASS F,VHARMLESS MEDICINES, TELMISARTAN TABLETS | $3.3M | 3 | 0.0% |
| 13 | MARKSANS PHARMA LIMITED | $2.6M | 3 | 0.0% |
| 14 | THE MADRAS PHARMACEUTICAL TELMISAR PLUS TABLET (TELMISARTAN 40MG &CRESAR 40 TABLETSTELMISARTAN TABLETS 40 MG - | $1.9M | 1 | 0.0% |
| 15 | PHARMAFABRIKON CRESAR 40 TABLETSTELMISARTAN TABLETS 40 MG -TELMISARTAN TABLETS 20 MG - | $1.8M | 1 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Telmisartan exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla has received approvals from the FDA, WHO-GMP, and EU GMP, indicating compl |
| MYLAN LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | Mylan Laboratories holds FDA, WHO-GMP, and EU GMP certifications, reflecting adh |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Intas Pharmaceuticals has obtained FDA, WHO-GMP, and EU GMP approvals, ensuring |
| ALEMBIC PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Alembic Pharmaceuticals has received FDA, WHO-GMP, and EU GMP certifications, in |
| GLENMARK PHARMACEUTICALS LIMITED | Warning Letter (July 2025 | Yes | Yes | Multiple | Glenmark Pharmaceuticals received an FDA warning letter in July 2025 for its Mad |
| MICRO LABS LIMITED | Approved | Yes | Yes | Multiple | Micro Labs Limited holds FDA, WHO-GMP, and EU GMP certifications, reflecting adh |
| MSN LABORATORIES PRIVATE LIMITED | Approved | Yes | Yes | Multiple | MSN Laboratories has obtained FDA, WHO-GMP, and EU GMP approvals, ensuring compl |
| TORRENT PHARMACEUTICALS LTD | Approved | Yes | Yes | Multiple | Torrent Pharmaceuticals holds FDA, WHO-GMP, and EU GMP certifications, indicatin |
| MARKSANS PHARMA LIMITED | Approved | Yes | Yes | Multiple | Marksans Pharma has received FDA, WHO-GMP, and EU GMP certifications, reflecting |
TransData Nexus reviewed the regulatory standing of 9 leading Telmisartan exporters from India. 8 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Telmisartan sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as "India's pharmaceutical capital," has a rich history in bulk drug manufacturing. The establishment of Indian Drugs and Pharmaceuticals Limited (IDPL) in 1961 marked the city's foray into the pharmaceutical sector. Over the decades, Hyderabad has attracted numerous national and global companies, solidifying its position as a hub for active pharmaceutical ingredients (APIs) production. As of 2010, the city manufactured one-third of India's bulk drugs and 16% of biotechnology products, contributing to its reputation as "India's pharmaceutical capital" and the "Genome Valley of India."
The city's infrastructure supports large-scale API manufacturing, making it a pivotal player in the supply chain for drugs like Telmisartan. Companies such as Natco Pharma, headquartered in Hyderabad, exemplify the region's capacity in producing both APIs and finished dosage formulations.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its prowess in pharmaceutical formulations. Gujarat's pharmaceutical industry ranks number one in India, with a 33% share in drug manufacturing and a 28% share in drug exports. The state boasts 130 USFDA-certified drug manufacturing facilities, with Ahmedabad and Vadodara being central to this success.
Vadodara, in particular, is home to Alembic Pharmaceuticals, one of India's oldest pharmaceutical companies, established in 1907. Alembic Pharmaceuticals produces formulations for therapeutic areas such as cardiology, dermatology, diabetes, ophthalmology, and infectious diseases for domestic and international markets.
The region's focus on formulations, combined with its robust infrastructure and regulatory compliance, positions it as a key player in the production and export of Telmisartan formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being the financial capital, hosts numerous pharmaceutical companies with extensive export operations. The proximity to major ports facilitates efficient international distribution, making this cluster vital for exporting drugs like Telmisartan to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical hub, primarily due to favorable tax incentives. The region offers benefits such as tax holidays and excise duty exemptions, attracting numerous pharmaceutical manufacturers. This cluster contributes substantially to the domestic supply chain, including the production of Telmisartan.
5Sourcing Recommendations
- Diversify Supplier Base: Given that CIPLA LIMITED accounts for 98.4% of Telmisartan exports, it's prudent to diversify sourcing to mitigate risks associated with supplier concentration.
- Engage with Emerging Manufacturers: Companies like MYLAN LABORATORIES LIMITED and INTAS PHARMACEUTICALS LIMITED, though currently holding smaller market shares, have the potential to scale up production. Establishing relationships with these manufacturers can provide alternative sourcing options.
- Leverage Regional Strengths: Utilize Hyderabad's capabilities in API production for raw material sourcing and Ahmedabad-Vadodara's expertise in formulations for finished products to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure that all suppliers adhere to international regulatory standards, such as those set by the USFDA and EMA, to maintain product quality and facilitate smooth export processes.
By strategically engaging with these pharmaceutical clusters and adhering to the outlined recommendations, TransData Nexus can enhance its supply chain resilience and capitalize on India's robust pharmaceutical manufacturing landscape.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Telmisartan exporters from India
Cipla Limited — Cipla acquires Ivia Beaute's personal care business for ₹130 crore
In April 2024, Cipla Limited acquired the distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore, with an additional ₹110 crore contingent on milestones. This acquisition aims to expand Cipla's consumer health portfolio by incorporating Ivia's personal care brands. IMPACT: This acquisition is not directly related to Telmisartan exports and is unlikely to impact Cipla's position in the Telmisartan market.
Impact: This acquisition is not directly related to Telmisartan exports and is unlikely to impact Cipla's position in the Telmisartan market.
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million
In 2025, Alembic Pharmaceuticals' U.S. subsidiary acquired Utility Therapeutics Ltd for $12 million, adding the FDA-approved urinary tract infection drug Pivya (pivmecillinam 185 mg) to its portfolio. IMPACT: This acquisition does not pertain to Telmisartan and is unlikely to affect Alembic's Telmisartan export activities.
Impact: This acquisition does not pertain to Telmisartan and is unlikely to affect Alembic's Telmisartan export activities.
Intas Pharmaceuticals Limited — Intas acquires Actavis UK and Ireland for £603 million
In 2017, Intas Pharmaceuticals' subsidiary, Accord Healthcare, acquired Actavis UK Ltd. and Actavis Ireland Ltd. from Teva Pharmaceutical Industries for £603 million, including a portfolio of generic medicines and a manufacturing plant in Barnstaple. IMPACT: This acquisition, occurring prior to the specified 18-month period, does not impact current Telmisartan export activities.
Impact: This acquisition, occurring prior to the specified 18-month period, does not impact current Telmisartan export activities.
Common Questions — Telmisartan Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which telmisartan supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 1,619 recorded shipments worth $10.8B. MYLAN LABORATORIES LIMITED (240 shipments) and INTAS PHARMACEUTICALS LIMITED (461 shipments) are also established high-volume exporters.
Q How many telmisartan manufacturers are there in India?
India has 413 active telmisartan exporters with a combined export market of $11.0B across 11,086 shipments to 132 countries. The top 5 suppliers hold 99.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for telmisartan from India?
Average FOB unit price: $5.49 per unit, ranging from $0.00 to $5219.14. Average shipment value: $990.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 413 verified Indian exporters of Telmisartan ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 11,086 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 132 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
11,086 Verified Shipments
413 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists